# A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

> **NCT03593109** · PHASE1 · TERMINATED · sponsor: **Second Affiliated Hospital of Xi'an Jiaotong University** · enrollment: 1 (actual)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

## Key facts

- **NCT ID:** NCT03593109
- **Lead sponsor:** Second Affiliated Hospital of Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-30
- **Primary completion:** 2021-05-01
- **Final completion:** 2021-05-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Suitable patients were not recruited
- **Last updated:** 2021-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03593109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03593109, "A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03593109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*